CAR T-cell Products Shine, Reveal New Insights CAR T-cell Products Shine, Reveal New Insights

The 12-month response and progression-free survival rates in 152 real-world patients treated with tisagenlecleucel (Kymriah) for an approved indication were 48.4% and 26.4%, respectively.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news